Increased use of therapeutic strategies targeting mIDH1 may therefore also increase the proportion of glioma patients harboring IDH2 mutations, underscoring the need for the development of brain-penetrating PET tracers that can reliably detect mutations in both isoforms. Here, IDH2 is linked to glioma.